To our knowledge, because of the low incidence rate of BRAF-mutated NSCLC in China, the efficacy and safety of anti-BRAF targeted therapy among BRAF-mutated Chinese NSCLC population in the real-world clinical practice remains unclear, the results of our study was of clinical importance. Here, BRAF is linked to non-small cell lung carcinoma.